BEAM: Beam Therapeutics Corp P/S Multiple

Brandmark of Beam Tx (BEAM)

Beam Therapeutics Inc. (BEAM) focuses on an innovative DNA base editing platform, diversifying risks across oncology and hematology. This P/S chart visualizes this market valuation, where the metric level stands at 16.10. The company develops one-time treatments for severe pathologies, attracting major partners. Simultaneously, the business is expanding its development portfolio for liver and blood disease therapies.

Beam Therapeutics Corp (BEAM) - P/S Multiple from 07/04/2022 to 11/15/2026

Beam Therapeutics Corp (BEAM) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart Beam Therapeutics|BEAM - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Beam Therapeutics|BEAM - Total Company Value
- balance sheet equity data:
Share Book Value Beam Therapeutics|BEAM - Book Capitalization|Market-to-Book Ratio beamtx.com|BEAM - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Beam Therapeutics Inc.|BEAM - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Beam Therapeutics Inc.|BEAM - Company Aggregate Debts|Debts to Net Assets Beam Tx|BEAM - Company Long-Term Debts|Company Current Liabilities Beam Therapeutics|Interim Coverage Ratio beamtx.com
- earnings and valuation multiples indicators:
BEAM - Net Income|Expected Net Income Beam Therapeutics Inc.|BEAM - P/E Multiple|Market Cap to Projected Earnings Beam Tx|BEAM - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Beam Tx|BEAM - Operating profit EBITDA|Net earnings per share for the last 12 months Beam Therapeutics|BEAM - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months beamtx.com|BEAM - Earnings growth in current year|Net earnings per share growth forecast for next year Beam Therapeutics Inc.
- issuer revenue and sales details:
BEAM - Revenue and Sales Volume|Company Expected Sales Volume Beam Therapeutics|BEAM - P/S Multiple|Forward P/S Multiple Beam Therapeutics
General company analysis:BEAM, Beam Therapeutics
Signature product of Beam Therapeutics Inc

The P/S multiple relates market capitalization to annual sales volume, measuring the premium the market is willing to pay per unit of revenue in anticipation of future growth. For Beam Therapeutics Inc. (BEAM), whose profitability remains hypothetical due to high clinical trial costs, the current price-to-sales ratio serves as an indicator of speculative expectations, allowing for an assessment of the premium paid for high-risk developments.

Competing companies

TEM (Tempus AI, Inc.) - Market Capitalization-to-Revenue Ratio|Qiagen Group - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IONS|RGEN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Avidity Biosciences RNA|CRSP: P/S Multiple|Market Cap to Revenue Ratio WGS|RARE (Ultragenyx Pharma) - P/S Multiple|P/S Multiple Sarepta Corp|Price-to-Revenue Ratio Twist Bioscience, Inc. (TWST)|Market Cap to Revenue 10x Genomics TXG|Price-to-Revenue Ratio Intellia Therapeutics NTLA|Market Cap to Sales Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Price-to-Revenue Ratio|Price to Sales Wave Pharma|mazetx.com (MAZE) - Price-to-Revenue Ratio|SION - Price-to-Revenue Coefficient|PRME (Prime Medicine Inc) - P/S Multiple|Taysha Gene Therapies, Inc. - Price-to-Sales Ratio|P/S Multiple QURE|MGTX: Price-to-Sales Ratio|Price-to-Revenue Ratio REGENXBIO RGNX|SLDB: Market Cap to Revenue Ratio|OCGN: Market Cap to Revenue|PACB - P/S Multiple|BNTC (Benitec Corp) - Market Cap to Revenue|Price-to-Revenue Multiple Design Corp DSGN|Price-to-Revenue Ratio Rocket Pharmaceuticals|P/S Multiple 4D Molecular Therapeutics, Inc.|Price-to-Revenue Ratio Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Market Capitalization-to-Revenue Ratio|P/S Multiple EDIT (Editas Medicine, Inc.)|P/S Multiple Silence Therapeutics Corp SLN|PRQR - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Codexis Inc CDXS|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio metagenomi.co|P/S Multiple Precision BioSciences Inc.|P/S Multiple GBIO|Boundless Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple XCUR (Exicure, Inc.)|Price-to-Revenue Coefficient Imunon, Inc. (IMNN)|PHIO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio MBIO (mustangbio.com)|RNAZ: P/S Multiple|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Corp) - P/S Multiple|BLUE: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ImmunoPrecise (IPA)|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals, Inc. - P/S Multiple|Price-to-Revenue Coefficient Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Unity Biotechnology, Inc - Market Capitalization-to-Revenue Ratio